Navigation Links
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Date:5/30/2008

temsirolimus may provide further evidence of clinical utility in advanced RCC," says Brian Rini, M.D., of the Cleveland Clinic Taussig Cancer Institute in Cleveland, and co-principal investigator of INTORACT.

RCC will account for approximately 85 percent of the estimated 54,390 new cases of kidney cancer that will be diagnosed in the United States annually, and about 40 percent of these patients will have advanced disease at the time of diagnosis. Clear-cell RCC accounts for about 75 percent of all RCC cases.

Wyeth is conducting a number of studies examining TORISEL in various settings. Additional information about TORISEL studies is available at http://www.clinicaltrials.gov.

About TORISEL

TORISEL is the only approved cancer therapy that specifically inhibits the mTOR kinase, an important regulator of cell proliferation, cell growth and cell survival. Inhibition of mTOR in treated cancer cells blocked the translation of genes that regulate the cell cycle. In in vitro studies using renal cancer cell lines, TORISEL inhibited the activity of mTOR and resulted in reduced levels of certain cell growth factors involved in the development of new blood vessels, such as vascular endothelial growth factor.

TORISEL is approved for the treatment of advanced RCC in the United States, European Union and other markets, based on results of a phase 3 clinical study that demonstrated that TORISEL improves overall survival for patients with advanced RCC compared with interferon-alfa.

Important Safety Information

Hypersensitivity reactions manifested by symptoms, including, but not limited to anaphylaxis, dyspnea, flushing, and chest pain have been observed with TORISEL. Serum glucose, serum cholesterol, and triglycerides should be tested before and during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
2. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
3. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
4. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
5. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
8. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
9. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
10. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. , Sept. 17, 2014  Neuraltus Pharmaceuticals, ... Company,s Phase 2 clinical program of NP001 for the ... Gehrig,s disease) are being highlighted today in an ... ALS Research Group , being held in ... a  post hoc  analysis, administration of a high dose ...
(Date:9/17/2014)... 2014  Fortune Oil and Gas, Inc. (OTCPink:FOGC), today ... Manzo Pharmaceuticals, Inc. with the symbol (OTCPink : FOGCD). ... 17, 2014. Also taking effect today is a ten ... a pivotal event in the company,s progress according to ... could not proceed with the plan and still have ...
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Auxilium Pharmaceuticals, ... company, today confirmed that Auxilium has received an unsolicited, ... ENDP ) to acquire all of the outstanding shares ... per share in cash and Endo stock, subject to ... the unsolicited, non-binding proposal that Auxilium received from Endo ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7
... CHICAGO, June 9, 2011 Today a Cook County jury ... Chicago area man, Steven Johansen, who was administered Baxter blood ...  This was the first of hundreds of pending lawsuits on ... are pending in the Circuit Court of Cook County in ...
... Inc. today announced an agreement with the U.S. Department of ... the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. ... this investigation occurred more than six years ago, and as ... United States since learning of the investigation in 2008. ...
Cached Medicine Technology:Nolan Law Group: Jury Finds Against Baxter Healthcare In Nation's First Contaminated Chinese Heparin Case 2UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities 2
(Date:9/17/2014)... 17, 2014 The International Journal of Surgery ... its archive of previously published content: after 24 months published ... aim of the IJS is to improve surgical ... making these articles available to all will improve efforts to ... IJS said, "The journal has always been a great ...
(Date:9/17/2014)... In ongoing coverage of formulary exclusion ... (DBN) continues to find criticism surrounding the tactic. ... issue , CVS Caremark Corp. and Express Scripts ... cut more drugs than ever, but industry consultants ... likely to achieve. Despite finding the strategy problematic, ...
(Date:9/17/2014)... New York, N.Y. (PRWEB) September 17, 2014 ... for fans taking part in the fitness industry’s most ... in Las Vegas, NV. Two fans will each take ... fully loaded with Neon Sport supplements and gear. Fitmark ... booth during the Olympia Expo, September 19-20th. , ...
(Date:9/17/2014)... Mission Viejo, CA (PRWEB) September 17, 2014 ... meetings and events, announced today it has released ... engagement at large meetings and corporate events. The ... up, enhance presentation and document management capabilities and ... speaker and participants. , Lintelus Meeting 3.1 ...
(Date:9/17/2014)... 2014 Market Research Report on ... in-depth research report on the China DEHP Plasticizer ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2Health News:Lintelus Energizes Audiences with the Latest Version Of its Multi-Screen Interactive Software 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 3
... 2012) According to the results of a new ... Journal of the American College of Surgeons , ... disease and were not meaningfully involved in treatment discussions ... As a result, the study,s investigators determined that there ...
... News) -- A drug commonly used to treat patients with ... older than 40 years who have Down syndrome and Alzheimer,s, ... animal studies of the Alzheimer,s drug, memantine, showed promising results ... with Down syndrome aged 40 and older revealed the opposite, ...
... January/February issue of Annals takes an up-close look ... a single individual, a phenomenon that is growing at an ... is estimated by the year 2020, 25 percent of the ... costs for managing these conditions will reach $1.07 trillion. In ...
... injury (AKI) has severe consequences, with a 25 to 80 ... to diagnose AKI using a urine test, enabling emergency departments ... the hospital. The study will be published online on January ... of Cardiology. Physicians typically measure a patient,s creatinine ...
... Steven Reinberg HealthDay Reporter , MONDAY, Jan. 9 ... heartbreaking grief, suggests new research that finds losing a loved ... a day of a significant other,s death, heart attack risk ... at data on nearly 2,000 heart attack patients. And within ...
... risk of suffering a heart attack increases by approximately 21 ... one, according to a study lead by researchers at Beth ... 9 online in the journal Circulation found the ... the first week after the death of a loved one, ...
Cached Medicine News:Health News:Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer 2Health News:Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer 3Health News:Alzheimer's Med Seems Ineffective in Those With Down Syndrome 2Health News:January/February 2012 Annals of Family Medicine 2Health News:January/February 2012 Annals of Family Medicine 3Health News:January/February 2012 Annals of Family Medicine 4Health News:January/February 2012 Annals of Family Medicine 5Health News:January/February 2012 Annals of Family Medicine 6Health News:January/February 2012 Annals of Family Medicine 7Health News:January/February 2012 Annals of Family Medicine 8Health News:January/February 2012 Annals of Family Medicine 9Health News:Biomarkers identify acute kidney injury in emergency patients 2Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:Heart attack risk rises after loss of loved one 2
... protection, our conventional aprons are ... sturdy 2 webbed straps that ... hook fasteners. The straps can ... the apron. Our conventional apron ...
Unshielded...
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... MOST Options System is designed to ... of the knee or hip to ... provides the potential for restoration of ... the requirements of a rotating hinge ...
Medicine Products: